ES2094702B1 - Composiciones farmaceuticas para la prevencion y el tratamiento de enfermedades cancerosas y procedimiento para su preparacion. - Google Patents

Composiciones farmaceuticas para la prevencion y el tratamiento de enfermedades cancerosas y procedimiento para su preparacion.

Info

Publication number
ES2094702B1
ES2094702B1 ES09550024A ES9550024A ES2094702B1 ES 2094702 B1 ES2094702 B1 ES 2094702B1 ES 09550024 A ES09550024 A ES 09550024A ES 9550024 A ES9550024 A ES 9550024A ES 2094702 B1 ES2094702 B1 ES 2094702B1
Authority
ES
Spain
Prior art keywords
prevention
treatment
cancer diseases
procedure
preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
ES09550024A
Other languages
English (en)
Other versions
ES2094702A1 (es
Inventor
Gyula Kulcsar
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
IMMUNAL KFT
Original Assignee
IMMUNAL KFT
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by IMMUNAL KFT filed Critical IMMUNAL KFT
Publication of ES2094702A1 publication Critical patent/ES2094702A1/es
Application granted granted Critical
Publication of ES2094702B1 publication Critical patent/ES2094702B1/es
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

COMPOSICIONES FARMACEUTICAS PARA LA PREVENCION Y EL TRATAMIENTO DE ENFERMEDADES CANCEROSAS Y PROCEDIMIENTO PARA SU PREPARACION. LA INVENCION SE REFIERE A COMPOSICIONES FARMACEUTICAS PARA LA PREVENCION Y EL TRATAMIENTO DE ENFERMEDADES CANCEROSAS Y A UN PROCEDIMIENTO PARA SU PREPARACION. LAS COMPOSICIONES COMPRENDEN COMO MINIMO TRES COMPUESTOS ACTIVOS QUE SE ENCUENTRAN EN EL SISTEMA CIRCULATORIO: COMO MINIMO UN AMINOACIDO, COMO MINIMO UNA VITAMINA Y COMO MINIMO UN COMPONENTE SELECCIONADO ENTRE EL GRUPO CONSISTENTE EN ADENINA, 2-DESOXI-D-RIBOSA, D-MANOSA, D-GLUCOSAMINA, ACIDO MALICO, ACIDO OXALACETICO Y TRIFOSFATO DE ADENOSINA. LAS COMPOSICIONES PUEDEN UTILIZARSE SIN EFECTOS SECUNDARIOS PARA LA PREVENCION DE ENFERMEDADES CANCEROSAS, PARA LA INHIBICION DE FORMACION DE TUMORES EN CASO DE SIDA Y TRASPLANTES, PARA EVITAR LA FORMACION DE METASTASIS Y PARA EL TRATAMIENTO DIRECTO, ADYUVANTE O COMBINADO Y CURA DE ENFERMEDADES CANCEROSAS.
ES09550024A 1993-11-09 1994-11-08 Composiciones farmaceuticas para la prevencion y el tratamiento de enfermedades cancerosas y procedimiento para su preparacion. Expired - Fee Related ES2094702B1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
HU9303171A HU213677B (en) 1993-11-09 1993-11-09 Pharmaceutical compositions for preventing and treating tumor diseases, and process for producing them

Publications (2)

Publication Number Publication Date
ES2094702A1 ES2094702A1 (es) 1997-01-16
ES2094702B1 true ES2094702B1 (es) 1998-02-16

Family

ID=10984131

Family Applications (1)

Application Number Title Priority Date Filing Date
ES09550024A Expired - Fee Related ES2094702B1 (es) 1993-11-09 1994-11-08 Composiciones farmaceuticas para la prevencion y el tratamiento de enfermedades cancerosas y procedimiento para su preparacion.

Country Status (18)

Country Link
EP (1) EP0679081B1 (es)
JP (1) JPH08508045A (es)
KR (1) KR100363779B1 (es)
CN (1) CN1128615C (es)
AT (1) AT408414B (es)
AU (1) AU682735B2 (es)
CA (1) CA2151826C (es)
CH (1) CH686867A5 (es)
CZ (1) CZ286633B6 (es)
DE (2) DE4498692T1 (es)
ES (1) ES2094702B1 (es)
FI (1) FI953369A0 (es)
HU (1) HU213677B (es)
NL (1) NL195007C (es)
PL (1) PL177981B1 (es)
RU (1) RU2138257C1 (es)
SE (1) SE521049C2 (es)
WO (1) WO1995013061A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5864024A (en) * 1994-07-11 1999-01-26 Glinskii; Guennadi Victor Synthetic glycoamines and methods for their use that affect cell adhesion, inhibit cancer cell metastasis, and induce apoptosis
EP0967984A1 (en) * 1997-03-04 2000-01-05 Peregrine Pharmaceutical, Inc. Composition and method for treating cancer and immunological disorders resulting in chronic conditions
RU2108786C1 (ru) * 1997-09-15 1998-04-20 Клавдия Степановна Евланенкова Средство для лечения онкологических больных
US6284786B1 (en) * 1999-02-16 2001-09-04 The Center For The Improvement Of Human Functioning, Int'l., Inc. Treatment of cancer using lipoic acid in combination with ascorbic acid
IT1312060B1 (it) * 1999-04-09 2002-04-04 Antibioticos Spa Uso dell'acido alfa lipoico nel trattamento antimetastatico.
ES2164013B1 (es) * 2000-04-14 2003-06-16 Consejo Superior Investigacion Glicosidos de n-acetil-6-o-(2,2-bis(hidroximetil)-3-hidroxipropil)-d-glucosamina, procedimiento de obtencion y uso en el tratamiento de tumores cerebrales.
KR100465229B1 (ko) * 2001-04-09 2005-01-13 주식회사 안지오랩 2-아미노-2-데옥시-ｄ-글루코피라노오즈 또는 그의약학적으로 허용가능한 염을 유효성분으로 하는 혈관신생억제용 약학적 조성물
WO2003030890A1 (fr) * 2001-10-05 2003-04-17 Tetsuro Asao Activateurs du systeme immunitaire
WO2003061568A2 (en) 2002-01-16 2003-07-31 Eliezer Rapaport Methods and therapeutic compositions in the treatment of advanced cancer
DK1824470T3 (da) * 2004-12-17 2014-08-18 Cash Alan Brian Fremgangsmåde til forlængelse af levetiden og forsinke starttidspunktet for alders-relateret sygdom
ATE547105T1 (de) * 2005-08-03 2012-03-15 Nat Cancer Ct Glucosamin und derivate davon als transglutaminase-inhibitoren zur verwendung in der behandlung von einer funktionsstörung des nervensystems
KR100878585B1 (ko) 2006-06-16 2009-01-15 국립암센터 글루코사민, 글루코사민 유도체 또는 이들의 염을 포함하는항암감작제
KR100780868B1 (ko) * 2006-07-10 2007-11-30 부경대학교 산학협력단 항암효과를 나타내는 4급 아미노 글루코사민 화합물
CN103720693A (zh) * 2011-11-15 2014-04-16 张始状 人体五种正常碱基在制备治疗肿瘤药物中的应用
CN102406649A (zh) * 2011-11-15 2012-04-11 张始状 人体五种正常碱基在制备治疗肿瘤药物中的应用
WO2015137383A1 (ja) * 2014-03-11 2015-09-17 味の素株式会社 癌化学療法の補助剤
RU2707554C1 (ru) * 2019-02-27 2019-11-28 Федеральное государственное бюджетное учреждение "Петербургский институт ядерной физики им. Б.П. Константинова Национального исследовательского центра "Курчатовский институт" (НИЦ "Курчатовский институт-ПИЯФ") Композиция, ингибирующая рост и выживаемость опухолевых клеток

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB931921A (en) * 1960-12-22 1963-07-24 Lab Roques Therapeutic compositions intended for the treatment of any hepatic malfunctionings
DE2021969A1 (de) * 1970-04-29 1971-11-18 Boettger Kg Pharmazeutische Un Verfahren zur Herstellung eiweissfreier Praeparate
FR2201879B2 (es) * 1972-05-19 1976-01-23 Tixier Georges Fr
FR2244468A1 (en) * 1973-07-31 1975-04-18 Passwater Richard Anticarcinogenic food supplements - contg antioxidants and S-contg amino acids
JPS5535049A (en) * 1978-09-04 1980-03-11 Otsuka Pharmaceut Factory Inc Amino acid transfusion for cancerous patient
US4880918A (en) * 1982-07-13 1989-11-14 Eliezer Rapaport Arrest and killing of tumor cells by adenosine 5-diphosphate and adenosine-5-triphosphate
US4647453A (en) * 1984-10-18 1987-03-03 Peritain, Ltd. Treatment for tissue degenerative inflammatory disease
DE3440090A1 (de) * 1984-11-02 1986-05-07 Novo-Med AG, Appenzell Aminosaeureloesungen enthaltendes arzneimittel zur therapie von krebserkrankungen und verfahren zu seiner herstellung
ATE54826T1 (de) * 1985-10-23 1990-08-15 Mulli Kurt Nachf Gmbh Thymusextraktfraktionen enthaltende pharmazeutische zusammensetzung.
DE3821043A1 (de) * 1988-06-22 1989-12-28 Fresenius Ag Dialysier- und spuel-loesung zur intraperitonealen verabreichung
US5780039A (en) * 1992-04-23 1998-07-14 Novartis Nutrition Ag Orally-ingestible nutrition compositions having improved palatability

Also Published As

Publication number Publication date
NL195007C (nl) 2003-06-10
CN1116406A (zh) 1996-02-07
PL177981B1 (pl) 2000-02-29
CN1128615C (zh) 2003-11-26
CH686867A5 (de) 1996-07-31
FI953369A (fi) 1995-07-07
CA2151826A1 (en) 1995-05-18
FI953369A0 (fi) 1995-07-07
AT408414B (de) 2001-11-26
HU9303171D0 (en) 1994-01-28
AU1074995A (en) 1995-05-29
WO1995013061A1 (en) 1995-05-18
EP0679081B1 (en) 2002-02-06
NL9420013A (nl) 1995-10-02
CA2151826C (en) 2008-06-17
CZ177395A3 (en) 1996-01-17
JPH08508045A (ja) 1996-08-27
ATA900894A (de) 2001-04-15
RU2138257C1 (ru) 1999-09-27
HU213677B (en) 1997-12-29
CZ286633B6 (cs) 2000-05-17
EP0679081A1 (en) 1995-11-02
DE69429806D1 (de) 2002-03-21
ES2094702A1 (es) 1997-01-16
PL309600A1 (en) 1995-10-30
SE9502474L (sv) 1995-07-06
DE4498692T1 (de) 1996-02-22
KR100363779B1 (ko) 2003-03-06
DE69429806T2 (de) 2002-09-12
AU682735B2 (en) 1997-10-16
SE9502474D0 (sv) 1995-07-06
SE521049C2 (sv) 2003-09-23

Similar Documents

Publication Publication Date Title
ES2094702B1 (es) Composiciones farmaceuticas para la prevencion y el tratamiento de enfermedades cancerosas y procedimiento para su preparacion.
ES2196181T3 (es) Derivados de purina y proceso para su preparacion.
WO2000056303A3 (en) Treatment of immune diseases
AR012671A1 (es) Composiciones farmaceuticas para el tratamiento o profilaxis de la constipacion, los usos de dichas composiciones y los procesos para prepararlos
BR0209658A (pt) Derivados de 4-amino-5-fenil-7-1ciclobutil-pirrolo [2,3-d] pirimidina
AR013001A1 (es) Derivados de la piperazina, procedimientos para prepararlos, las composiciones farmaceuticas que los contienen, su utilizacion como medicamentoy el metodo para tratar enfermedades mediadas por la taquinina.
MXPA04012965A (es) Inhibidores virales.
ES2147294T3 (es) Compuestos terapeuticos.
BRPI0207961A8 (pt) Uso de análogos de epotilona e capecitabina para fabricar medicamento para tratar tumores cancerosos sólidos e kit compreendendo os referidos compostos.
BR0309875A (pt) métodos e composições para tratamento de distúrbios do sistema nervoso periférico e novos compostos úteis para isto
BR0313743A (pt) Benzimidazol quinolinonas e usos destas
BR0114799A (pt) Compostos de ácido cianofenoxi carboxìlico e composições para liberar agentes ativos
BR0312232A (pt) Inibidores de caspases e seus usos
EE200200565A (et) Vaskulaarse kahjustava toimega kombinatsioonravi
AR026197A1 (es) Uso de dipiridamol o mopidamol para el tratamiento y prevencion de trastornos de la microcirculacion dependientes de fibrina
WO2002079169A8 (en) Cyano-substituted dihydropyrimidine compounds and their use to treat diseases
AR024380A1 (es) Tienopirimidinas
BRPI0409884A (pt) compostos, composições farmacêuticas, método para o tratamento ou porfilaxia de doenças, e, usos de compostos e de um ou mais compostos em combinação com outros compostos farmacologicamente ativos
SE8304408D0 (sv) Desoxyuridine derivatives, processes for their preparation and their use as pharmaceuticals
BR0213037A (pt) Derivados de pirimidina
PT1109814E (pt) 5-heterociclil pirazol¬4,3-d|pirimidina-7-onas para o tratamento da disfuncao erectil masculina
NZ324380A (en) Therapeutic benzimidazole compounds and their use in treatment of virus infections
ES2189956T3 (es) Derivados de quinolina, procedimientos para su preparacion y su uso como medicamentos.
ECSP056190A (es) Compuestos utiles en la terapia de la enfermedad de alzheimer y formulaciones que los contienen
BRPI0414139A (pt) métodos e composições para tratar infecções por herpes

Legal Events

Date Code Title Description
EC2A Search report published

Date of ref document: 19970116

Kind code of ref document: A1

Effective date: 19970116

FD2A Announcement of lapse in spain

Effective date: 20150826